Claire Swift

Claire Swift

Auto-generated profile, based on publicly available information

Claire Swift

Ralph Lauren Centre for Breast Cancer Research, London, UNITED KINGDOM

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MCMaria Coakley
Maria Coakley
GVGuillermo Villacampa
Guillermo Villacampa
PSPrithika Sritharan
Prithika Sritharan
CSClaire Swift
Claire Swift
KDKathryn Dunne
Kathryn Dunne
NTNicholas C. Turner
Nicholas C. Turner
Purpose: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown. Experimental Design: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays for ctDNA molecular residual disease (MRD) detection in early-stage triple-negative breast cancer. We compared tumor-informed dPCR assays with tumor-informed personalized multimutation sequencing assays in 141 patients from cTRAK-TN. Results: MRD was first detected by personalized sequencing in 47.9% of patients, 0% first detected by dPCR, and 52.1% with both assays simultaneously (P < 0.001; Fisher exact test). The median lead time from ctDNA detection to relapse was 6.1 months with personalized sequencing and 3.9 months with dPCR (P = 0.004, mixed-effects Cox model). Detection of MRD at the first time point was associated with a shorter time to relapse compared with detection at subsequent time points (median lead time 4.2 vs. 7.1 months; P = 0.02). Conclusions: Personalized multimutation sequencing assays have potential clinically important improvements in clinical outcome in the early detection of MRD.

25 July 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JPJavier Pascual
Javier Pascual
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
PPPaula Z Proszek
Paula Z Proszek
CZChristoph Zielinski
Christoph Zielinski
ARAlistair Reay
Alistair Reay
MMMiguel Martin
Miguel Martin
Purpose: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations between baseline genomic landscape and on-treatment ctDNA dynamics with treatment efficacy. Experimental Design: Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model. Results: 201 patients were profiled at baseline, with ctDNA detection associated with worse progression-free survival (PFS)/overall survival (OS). Detectable TP53 mutation showed worse PFS and OS in both treatment arms, even after restricting population to baseline ctDNA detection. ESR1 mutations were associated with worse OS overall, which was lost when restricting population to baseline ctDNA detection. PIK3CA mutations confer worse OS only to patients on the palbociclib+fulvestrant treatment arm. ctDNA dynamics analysis (n = 120) showed higher ctDNA suppression in the capecitabine arm. Patients without ctDNA suppression showed worse PFS in both treatment arms. Conclusions: We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with hormone receptor–positive/HER2-negative metastatic breast cancer harboring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted.

1 December 2021 in International Journal of Psychophysiology
Verified
Journal Article
Open access
AEAnastasia Ejova
Anastasia Ejova
NBNicholas A. Badcock
Nicholas A. Badcock
SMSarah McKerchar
Sarah McKerchar
ABAlissa P. Beath
Alissa P. Beath
CSClaire Swift
Claire Swift
MJMichael P. Jones
Michael P. Jones
Debate continues as to whether an attentional bias towards threat displayed by sufferers of functional gastrointestinal disorders (FGIDs) is conscious and, thus, more amenable to change through psychological therapy. We compared the amplitudes of early (unconscious) and later (conscious) electroencephalographic (EEG) event-related potentials following silent reading of symptom-related, emotionally neutral, and emotionally negative nouns across two participant groups: 30 female FGID-sufferers who met diagnostic criteria for irritable bowel syndrome or functional dyspepsia, and 30 female healthy controls. Analogous indices based on alpha desynchronization were also examined, as were correlations between the EEG-based indices and a range of psychosocial variables. FGID-sufferers displayed marginally significantly higher occipital EPN amplitudes for all nouns, indicating marginally higher levels of unconscious attention in the task. FGID-sufferers also displayed, for negative as compared to neutral nouns, significantly lower central N400 amplitudes indicative of higher conscious attention. The result was only apparent in post-hoc pairwise comparisons, however. Uniquely among FGID-sufferers, central N400 was strongly negatively correlated with a range of negative psychosocial traits and states. The findings provide preliminary evidence of hypervigilance to general (as opposed to symptom-specific) threat among FGID-sufferers. Amidst concerns over Type I error, recommendations are made for fine-tuning the operationalisation of unconscious and conscious attentional bias in this population.

25 November 2025
Verified
Other
Open access
JPJavier Pascual
Javier Pascual
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
PPPaula Z Proszek
Paula Z Proszek
CZChristoph Zielinski
Christoph Zielinski
ARAlistair Reay
Alistair Reay
MMMiguel Martin
Miguel Martin
Supplementary Table 8. Summary of baseline ESR1 and PIK3CA mutations, with number of affected patients and mean VAF.

25 November 2025
Verified
Other
Open access
JPJavier Pascual
Javier Pascual
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
PPPaula Z Proszek
Paula Z Proszek
CZChristoph Zielinski
Christoph Zielinski
ARAlistair Reay
Alistair Reay
MMMiguel Martin
Miguel Martin
Supplementary Table 2. Complete table results for all patients (n=201) involved in baseline (C1D1) analysis.

25 November 2025
Verified
Other
Open access
JPJavier Pascual
Javier Pascual
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
PPPaula Z Proszek
Paula Z Proszek
CZChristoph Zielinski
Christoph Zielinski
ARAlistair Reay
Alistair Reay
MMMiguel Martin
Miguel Martin
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).